drugset / Trial / NCT03939702

Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants

NCT03939702

Phase 1 Completed 9 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelHealth-services research

Summary

This is an ADME study. Human radiolabeled mass balance studies are performed as part of drug development to obtain information about the absorption, distribution, metabolism, and excretion (ADME) of a study treatment. The goals of human ADME studies include the assessment of absorption, distribution, routes and rates of excretion, mass balance, and metabolite profile and identification.

Timeline

Start
2019-05-02
Primary completion
2019-07-11
Completion
2019-07-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Milvexian Small molecule 200 mg Oral

Indications